PETMED EXPRESS INC (PETS) research
PETMED EXPRESS INC- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- Last price
- $1.36
- As of
PETMED EXPRESS INC (PETS): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-28.
As of . Source: SEC EDGAR filings for PETS. Method and limitations.
Share the PETS intelligence card
See the full PETS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PETS on one page. Preview it with sample data, then open it live with a free account.
Preview the PETS dossierActive signals for PETS
- mediumEARNINGS_MISS
Q1-2027: Missed consensus by 328.8%, EPS $-0.28 vs $0.1224 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +250% to PETS (2026Q2)
- mediumEARNINGS_MISS
Q3-2026: Missed consensus by 717.0% - EPS $-0.5 vs $-0.0612 estimate
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 296.1% - EPS $0.11 vs $-0.0561 estimate
- lowEARNINGS_MISS
Q3-2025: EPS $-0.03 vs $-0.0051 estimate, -0.02 on a near-zero consensus
FREE, NO ACCOUNT
Every signal on PETS, as it fires
You are seeing 5 of 7 signals recorded on PETS since 2026-06-05.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PETS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 716382106 · 2026Q2 | $2.2M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 716382106 · 2026Q2 | $142K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PETS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
PETS against its peers
PETS's operating margin of -32.8% ranks in the 44th percentile of 7 Pharmaceutical Retailers sub-industry peers, fiscal periods ending between 2025-10-31 and 2026-03-31.
| Metric | PETS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 179M USD | 3.2M USD | 93 | 6 |
| Revenue YoY | -21.1% | n/a | n/a | 3 |
| Gross margin | 28.1% | 41.5% | 44 | 7 |
| Operating margin | -32.8% | -29.7% | 44 | 7 |
| Net margin | -32.0% | -32.7% | 56 | 7 |
| Return on equity | -197.9% | -50.0% | 25 | 5 |
Peers (8): SHFH, BHIC, SCNX, POM, PMHS, HITI, RDGT, RTEZ. Left out: BLMH (no annual filing), DHTI (period gap), PNPL (period gap), TELYF (no annual filing). Fiscal periods ending between 2025-10-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (PETS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more PETS signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to PETSand get the insider, 13F, options, and confluence read in one view.